CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy

Annual Review of Immunology

Volumn 19, Issue , 2001, Pages 565-594

  Chambers, C A ^a   Kuhns, M S ^a   Egen, J G ^a   Allison, J P ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

CD28; Costimulation; Cytotoxic T lymphocyte antigen 4 (CTLA 4); T cell activation; T cell regulation

Indexed keywords

CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; T LYMPHOCYTE RECEPTOR;

CANCER IMMUNOTHERAPY; CELL CYCLE; CELLULAR IMMUNITY; CLONAL ANERGY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSTIMULATION; LYMPHOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR IMMUNITY;

ADENOCARCINOMA; AMINO ACID MOTIFS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, DIFFERENTIATION; CELL CYCLE; CELL DIFFERENTIATION; CLONAL ANERGY; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOCONJUGATES; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOPROLIFERATIVE DISORDERS; MACROMOLECULAR SUBSTANCES; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; MODELS, IMMUNOLOGICAL; NEOPLASMS; PROSTATIC NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 0035056017     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.19.1.565     Document Type: Review

References (140)

1. Clonal expansion versus functional clonal inactivation: A costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy
2. CD28/B7 system of T cell costimulation
3. A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes
4. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells
5. CD28 mediated signalling costimulates murine T cells and prevents the induction of anergy in T cell clones
6. Activation and differentiation requirments of primary T cells in vitro
7. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and Interleukin 2 mRNA accumulation
8. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation
9. T cell co-stimulation and in vivo tolerance
10. Differential T cell costimulatory requirements in CD28-deficient mice
11. Duration of TCR stimulation determines costimulatory requirement of T cells
12. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation
13. A new member of the immunoglobulin superfamily CTLA-4
14. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors
15. CTLA-4 is a second receptor for the B cell activation antigen B7
16. Covalent Dimerization of CD28/CTLA-4 and oligomerization of CD80/86 regulate T cell costimulatory interactions
17. The emerging role of CTLA-4 as an immune attenuator
18. CTLA-4 can function as a negative regulator of T cell activation
19. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
20. + T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4
21. Superantigen responses and costimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo
22. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4
23. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
24. Thymocyte differentiation occurs normally in the absence of CTLA-4
25. The Fas death factor
26. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor
27. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease
28. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor
29. + T cells
30. Molecular basis of T cell inactivation by CTLA-4
31. Regulation of T cell receptor signaling by tryosine phosphatase SYP association with CTLA-4
32. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice
33. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)
34. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses
35. Normal thymic selection, normal viability and decreased lymphoproliferation in T cell receptor-transgenic CTLA-4-deficient mice
36. + T cells
37. +) T cell responses
38. The role of CTLA-4 in regulating Th2 differentiation
39. CTLA-4: The costimulatory molecule that doesn't: Regulation of T cell responses by inhibition
40. Normal responsiveness of CTLA-4-deficient anti-viral cytoxic T cells
41. Differential role of CTLA-4 in regulation of resting memory versus naive CD4 T cell activation
42. Phenotypic analysis of CTLA-4 and CD28 expression during transient peptide-induced T cell activation in vivo
43. CTLA-4 mediates antigen-specific apoptosis of human T cells
44. + T lymphocytes induced by CTLA-4 crosslinking
45. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells
46. CTLA-4 ligation blocks CD28-dependent T cell activation
47. 2-terminal kinase (JNK) activation, but does not affect phophorylation of T cell receptor and ZAP70
48. +) T cells
49. CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X1 induction
50. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death
51. Regulation of T-cell lymphokine gene transcription by the accessory molecule CD28
52. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway
53. CTLA-4-mediated inhibition of early events of T cell proliferation
54. Characterization of CTLA-4 structure and expression on human T cells
55. Cytotoxic T lymphocyte-associated molecule-4, a high avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail
56. Augmentation of CTLA-4 expression by wortmannin: Involvement of lysosomal sorting properties of CTLA-4
57. Cytolytic T lymphocyteassociated antigen-4 and the TCRζ/CD3 comples, but not CD28, interact with clathrin adaptor complexes AP-1 and AP-2
58. Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2
59. Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression
60. Interaction of the cytoplasmic tail of CTLA-4 (CD152) with a clathrin- associated protein is negatively regulated by tyrosine phosphorylation
61. Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein
62. Defective CTLA-4 cycling pathway in Chediak-Higashi syndrome: A possible mechanism for deregulation of T lymphocyte activation
63. CD28 receptor endocytosis is targeted by mutations that disrupt phosphatidylinositol 3-kinase binding and costimulation
64. The murine homolog of the T lymphocyte antigen CD28: Molecular cloning and cell surface expression
65. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement
66. The specific direct interaction of helper T cells and antigen-presenting B cells. II. Reorientation of the microtubule organizing center and reorganization of the membrane-associated cytoskeleton inside the bound helper T cells
67. CD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sites
68. JNK is involved in signal integration during costimulation of T lymphocytes
69. Selective modulation of protein kinase C-theta during T-cell activation
70. A receptor/cytoskeletal movement triggered by costimulation during T cell activation
71. The immunological synapse: A molecular machine controlling T cell activation
72. T lymphocyte costimulation mediated by reorganization of membrane microdomains
73. Membrane rafts and signaling by the multichain immune recognition receptors
74. Signaling through CD28/CTLA-4 family receptors: Puzzling participation of phosphatidylinositol-3 kinase
75. Immunoreceptor tyrosine-based inhibition motifs
76. The role of tyrosine phosphorylation and PTP-1C in CTLA-4 signal transduction
77. Regulation of cytotoxic T lymphocyte-associated molecule-4 by Src kinases
78. Tyrosine phosphatase SHP-2 binding to CTLA-4: Absence of direct YVKM/YFIP motif recognition
79. Janus kinase 2 is associated with a box 1-like motif and phosphorylates a critical tyrosine residue in the cytoplasmic region of cytotoxic T lymphocyte associated molecule-4
80. The CD28 and CTLA-4 receptors associated with the serine/threonine phosphatase PP2A
81. Cytotoxic T lymphocyte antigen 4 (CTLA-4) interferes with extracellular signal-regulated kinase (ERK) and Jun NH2-terminal kinase (JNK) activation, but does not affect phosphorylation of T cell receptor zeta and ZAP70
82. Cytotoxic T lymphocyte antigen 4 (CTLA-4) engagement delivers an inhibitory signal through the membrane-proximal region in the absence of the tyrosine motif in the cytoplasmic tail
83. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression
84. The inhibitory function of CTLA-4 does not require its tyrosine phosphorylation
85. Structural analysis of CTLA-4 function in vivo
86. Structure and dimerization of a soluble form of B7-1
87. Structure of murine CTLA-4: A novel dimer modulating T cell responsiveness
88. The ups and downs of costimulation
89. The role of CTLA-4 in the regulation and initiation of T cell responses
90. CTLA-4 regulates the unfolding of autoimmune diabetes
91. Pinpointing when CTLA-4 must be engaged to dampen diabetogenic T cells
92. ZAP-70 is constitutively associated with tyrosine-phosphoryated TCR z in murine thymocytes and lymph node cells
93. Selecting and maintaining a diverse T-cell repertoire
94. Long-term survival but impaired homeostatic proliferation of naive T cells in the absence of p56(ck)
95. + T cell survival is not directly linked to self-MHC-induced TCR signaling
96. Two distinct mechanisms lead to impaired T cell homeostasis in JAK3- and CTLA-4-deficient mice
97. H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection
98. Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway
99. CTLA-4: A negative regulator of autoimmune disease
100. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis
101. Specific blockade of CTLA-4/B7 inter-actions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis
102. CTLA-4 downregulates epitope spreading and mediates remission in relapsing experimental autoimmune encephalomyelitis
103. CTLA-4 blockade synergizes with tumor-derived GM-CSF for treatment of an experimental mammary carcinoma
104. Combination immunotherapy of B16 melanoma using anti-CTLA-4 and GM-CSF producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
105. Combination immunotherapy of primary prostate cancer in a transgenic model using CTLA-4 blockade
106. + T cell help
107. CTLA-4 regulates the size, function, and reactivity of a primed pool of T cells
108. Expression and function of CTLA-4 in Th1 and Th2 cells
109. + T cells toward the Th1 subset by CTLA-4 costimulation
110. CTLA-4 regulates tolerance induction and T cell differentiation in vivo
111. Protective immunity to nematode infection is induced by CTLA-4 blockade
112. CTLA4 (CD152) modulates the Th subset response and alters the course of experimental Leishmania major infection
113. Cytotoxic T lymphocyte antigen 4 (CD152) regulates self-reactive T cells in BALB/c but not in the autoimmune NOD mouse
114. + T cell responses: The alternative approaches
115. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation
116. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement
117. Role of interleukin 12 and costimulation in T cell anergy in vivo
118. + T cells
119. Induction of T cell anergy in the absence of CTLA-4/B7 interaction
120. TGF-β mediates CTLA-4 suppression of cellular immunity in murine kalaazar
121. Cutting edge: Lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous
122. Regulatory T cells in autoimmmunity
123. + immunoregulatory T cells that control autoimmune diabetes
124. +) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
125. +) regulatory cells that control intestinal inflammation
126. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production
127. Manipulation of costimulatory signals to enhance antitumor T-cell responses
128. Enhancement of antitumor immunity by CTLA-4 blockade
129. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages
130. Manipulation of T cell activation to generate antitumor CTLs
131. +T cell and IL-2 dependent mechanism
132. In vivo blockade of CTLA-4 enhances the priming of responsive T-cells but fails to prevent the induction of tumor antigen-specific tolerance
133. Vaccination with irradiated tumor cells engineered to secrete GM-CSF stimulates potent, specific, and long lasting anti-tumor immunity
134. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
135. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapytreated tumor-bearing mice
136. Elimination of residual metastatic prostate cancer following surgery and adjuncitve CTLA-4 blockade immunotherapy
137. + T cells in the antitumor immune response